Tecentriq (Atezolizumab) for Lung Cancer | MyLungCancerTeam

Connect with others who understand.

sign up Log in
About MyLungCancerTeam
Powered By

Tecentriq is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with small cell or non-small cell lung cancer by itself or as an adjuvant therapy (in combination with other drugs). Tecentriq is also referred to by its drug name, atezolizumab.

Tecentriq is a member of a class of drugs called monoclonal antibodies. Tecentriq is believed to work by binding to a receptor on cancer cells known as programmed death-ligand 1 (PD-L1). This prevents PD-L1 from interacting with certain chemical messengers, which allows the body’s antitumor immune response to attack the cancerous cells, thus slowing tumor growth.

How do I take it?
Prescribing information states that Tecentriq is given as an IV injection (into your vein) by a health care professional. Tecentriq is usually given in a health clinic or doctor’s office once every two, three, or four weeks. It should be administered according to the frequency specified by the physician.

Tecentriq is available only as an IV injection.

Side effects
The FDA-approved label for Tecentriq lists common side effects including fatigue, weakness, nausea, constipation, diarrhea, decreased appetite, and hair loss.

Rare but serious side effects listed for Tecentriq include fetal harm and infusion reactions.

For more details about this treatment, visit:

Tecentriq (Atezolizumab) — Genentech

Atezolizumab (Intravenous Route) — Mayo Clinic

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in